Immune Monitoring with ImmuKnow(R) in Islet Transplantation May Prove Useful in Reducing the Potential Risks of Rejection, Infection and Other Complications Following Transplant
The results of these studies will be presented during the American Transplant Congress in
Dr. Mineo explained that monitoring immune function following pancreatic islet transplantation has been a complex procedure based on a variety of measures, such as reactive antibodies, drug levels, metabolic parameters and clinical status. “By themselves, none of these measures can be used to reliably predict clinical outcomes in these patients,” said Dr. Mineo. “The results of our study support the use of the ImmuKnow assay to reduce the risk of graft failure, infections or drug toxicity in islet transplant patients.”
These results are in agreement with a report from Baylor Research Institute’s study of patients at
The use of the ImmuKnow assay as described in these studies has not been cleared by the U.S. Food & Drug Administration.
ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.
The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient.
About Cylex, Inc.
Cylex is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout
SOURCE Cylex, Inc.